• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Mission Bio Unveils Industry-First Single-Cell Genotype and Targeted Gene Expression Solution

by Syed Hamza Sohail 06/05/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells.

– The assay, which can be leveraged for Phase 2 or 3 trials to home in on patients most likely to benefit from a cancer therapy, will be unveiled at the European Hematology Association (EHA) meeting in Milan, Italy.

Mission Bio Launches Multi-Modal Single-Cell Assay to Advance Precision Oncology

Mission Bio has introduced a new Single-Cell Genotype and Targeted Gene Expression assay as part of its Pharma Assay Development (PAD) services, offering end-to-end support from custom assay design to data interpretation and technology transfer. This multi-modal assay provides pharmaceutical partners with a high-resolution understanding of cancer cell behavior, with three primary applications: uncovering mechanisms of therapeutic resistance, informing next-generation T-cell therapy design, and improving patient selection in clinical trials.

The assay is specifically designed to overcome challenges in characterizing tumor heterogeneity and resistance pathways—persistent bottlenecks in oncology drug development. Existing methods often fall short of providing integrated insights across genomic and transcriptomic layers. By capturing both genomic mutations and targeted gene expression changes within the same cell, the enhanced Tapestri Platform delivers a unified, high-resolution view of treatment response and disease progression, helping de-risk late-stage development.

Mission Bio CEO Brian Kim noted that most clinical failures in hematologic oncology occur during Phase II or III trials due to poor patient response and a lack of robust predictive biomarkers. He emphasized that this new capability helps identify which patients are most likely to respond to specific therapies, aligning with Mission Bio’s broader goal of enabling precision medicine through single-cell analytics.

The assay also includes sample multiplexing, reducing the cost of single-cell analysis by approximately 60% compared to using separate technologies for similar insights. Early adopters of the Tapestri Platform have already integrated targeted gene expression with single-cell genotyping and multi-omics workflows, highlighting its utility in applications such as tracking clonal evolution and resistant subclones in AML under therapeutic pressure.

Future development by the PAD team will include adding immunophenotyping to the assay, enabling true multi-omic profiling at the single-cell level for deeper insights into tumor-immune interactions and therapeutic impact.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |